We are live on ! Find out more
CLRBW

Cellectar Biosciences, Inc.
CLRBW

Delisted

CLRBW was delisted on the 20th of August, 2019.

Back to rankings

5 hedge funds and large institutions have $13K invested in Cellectar Biosciences, Inc. in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more capital invested

Capital invested by funds: $6K → $13K (+$7K)

25% more funds holding

Funds holding: 4 → 5 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.98K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$25
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$10K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$3K +$7.98K +32,241 New
UBS Group
3
UBS Group
Switzerland
– -$25 -100 -18%

CLRBW Hedge Fund Activity: Q2 2018 in Review

5 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q2 2018, worth a combined $13K — up 117% from $6K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CLRBW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $7.98K. The largest seller was UBS Group, cutting an estimated $25.

  • 5 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q2 2018, up from 4 in Q1 2018.
  • Funds reported $13K of Cellectar Biosciences, Inc. stock for Q2 2018, up 117% quarter-over-quarter.
  • 1 fund opened new Cellectar Biosciences, Inc. positions in Q2 2018 and 0 closed out, a net change of +1 holder.
  • The largest Cellectar Biosciences, Inc. buyer in Q2 2018 was Susquehanna International Group, an estimated $7.98K added.
  • The largest Cellectar Biosciences, Inc. seller in Q2 2018 was UBS Group, an estimated $25 sold.

Based on aggregated 13F filings for Q2 2018.